Vote Scores

Home / Companies / PTC Therapeutics, Inc. / 18 Jun 2024

Meeting · year to 30 June 2024306 filers reporting

PTC Therapeutics, Inc.: meeting of 18 Jun 2024

Votes reported on Form N-PX, item by item

306 Form N-PX filers reported votes at the PTC Therapeutics, Inc. meeting of 18 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

4 nominees; 94.2% of reported votes for; 14 filers withheld from or voted against at least one nominee.

961 vote records from 121 filers. 6 of the 121 filers that marked the item either way voted against management.

95.0% for0.0% against5.0% other5.0% against management121 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

474 vote records from 302 filers. 28 of the 293 filers that marked the item either way voted against management. 9 filers reported this item without a management mark.

88.1% for8.3% against3.6% other9.6% against management302 filers98.9% for1.0% against0.2% other1.1% against management82,589,783 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

240 vote records from 120 filers. 1 of the 120 filers that marked the item either way voted against management.

99.2% for0.0% against0.8% other0.8% against management120 filers100.0% for0.0% against0.0% other0.0% against management28,359,442 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalNo reportForNo report
State Street and SPDRForForFor
American CenturyForForFor
Franklin TempletonForForFor
InvescoForAgainst *For
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsForForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertForForFor
J.P. MorganForForFor
Goldman SachsForForFor
PGIM and PrudentialForForFor
Northern Trust and FlexSharesForForFor
SEIForForFor
T. Rowe PriceAbstain or withhold *ForFor
ThriventForForFor
Lincoln FinancialForForFor
VoyaForForFor
First TrustForForFor
Russell InvestmentsForForFor
NationwideForForFor
Victory CapitalForForFor
Brighthouse FundsAbstain or withhold *ForFor
Guggenheim and RydexForForFor
Columbia ThreadneedleForAgainst *For
BNY MellonForForFor
PrincipalForForFor
Pacific Life fundsForForFor
Global XForForFor
TransamericaAbstain or withhold *ForFor
AllianceBernsteinNo reportForNo report
Hartford FundsForForFor
DWSForForFor
MassMutualForForFor
Harbor FundsForForFor
Janus HendersonForForFor
Neuberger BermanNo reportForNo report
Natixis and Loomis SaylesNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the PTC Therapeutics, Inc. meeting?

306 Form N-PX filers reported votes at the meeting of 18 Jun 2024. On say-on-pay, 28 of 293 voted against management (9.6%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by PTC Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for PTC Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing PTC Therapeutics, Inc. with a meeting date within three days of 18 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.